Last reviewed · How we verify
Rebif® New Formulation
At a glance
| Generic name | Rebif® New Formulation |
|---|---|
| Also known as | Interferon beta1-A |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Oral Cladribine in Early Multiple Sclerosis (MS) (PHASE3)
- A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) (PHASE2)
- Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) (PHASE3)
- Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis (PHASE3)
- Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
- Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
- A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis (PHASE3)
- Transition to Rebif New Formulation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rebif® New Formulation CI brief — competitive landscape report
- Rebif® New Formulation updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI